-

Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT.

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

Industry:

Definium Therapeutics, Inc.

NASDAQ:DFTX
Release Versions
English

Contacts

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
ir@definiumtx.com

Media Contact:
media@definiumtx.com

More News From Definium Therapeutics, Inc.

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the launch of Wired for Worry, a new healthcare provider disease education initiative focused on generalized anxiety disorder (GAD). Wired for Worry is designed to meet a critical need to broaden understanding of GAD through...

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced results from a new healthcare claims study of treatment patterns of newly diagnosed and established GAD patients, including pharmacotherapy use, discontinuation, switching and treatment progression. The fi...

Definium Therapeutics Announces New Employee Inducement Grants

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to eight newly hired non-executive employees consisting of options to purchase an aggregate of 169,740 common shares of the Company (the "Options") with effective grant dates of July 6, 2026...
Back to Newsroom